AMH Aged Care Companion - 2025 Online Content Update

The May 2025 Online content has been released. This update includes new information and a number of changes relevant to the use of medicines in older people.

Some updated topics that may be of interest include:

  • atrial fibrillation, community-acquired pneumonia, immunisation, inhaler devices, open-angle glaucoma, oral anticoagulation, orthostatic (postural) hypotension, osteoporosis, prostatitis, and urinary tract infections.

Many changes are made in every update of the ACC; these are outlined in the Summary of key changes. You should make checking this summary one of the first things you do with every new release.

AMH 2025 Release

The 2025 AMH has been released; here are some changes that may interest you:

  • new drugs, eg anifrolumab for systemic lupus erythematosus, inclisiran for hypercholesterolaemia, nirsevimab for prevention of RSV infection
  • new indications, including semaglutide or tirzepatide for weight management, zoledronic acid for adjuvant treatment of breast cancer
  • information on routine vaccines for adults and children is now presented in table format
  • revised tables of fungal and bacterial organism susceptibilities
  • new drug interactions, eg diltiazem + apixaban, diltiazem + rivaroxaban
  • ranitidine monograph reinstated, as TGA-approved products are available again

See the Summary of key changes for all new and deleted drugs.

If you’re new to AMH, make sure you watch our videos.

Find out more

AMH Children's Dosing Companion Online - January 2025 Updates

The updated version of the AMH Children’s Dosing Companion includes new monographs and dose changes. Specific changes of interest include:

  • a new monograph for semaglutide for weight management in obesity in adolescents; a dose for this indication has also been added to liraglutide
  • a new monograph for nirsevimab for babies and infants to prevent respiratory syncytial virus (RSV) disease
  • the TGA contraindicates use of promethazine in children under 6 years of age because of safety issues, especially as it is an over-the-counter product
  • a new oral agent, patiromer, for hyperkalaemia
  • an old drug that was discontinued - ranitidine - has been re-marketed and so we've re-instated the monograph

Many small but important changes are made in every update of the CDC; these are outlined in the Summary of key changes. You should make checking this summary one of the first things you do with every new release.

Find out more

Beware - buying electronic AMH products from other sources

Electronic versions of all AMH products are ONLY available for purchase from the AMH website. Any other website advertising the sale of AMH products may contain malicious software that may harm the integrity of your computer.

Likewise, any unauthorised email offer on these products could be spam. If you are unsure of its content, please delete the email and report the incident to us via sales@amh.net.au

To buy AMH print products, please go to the support page of the AMH website and select AMH Stockists found under the heading Where to buy AMH products.